18th Jul 2007 07:00
Vectura Group PLC18 July 2007 Not for release or distribution or publication in whole or part in or into the United States, Canada, Japan or Australia Vectura Group PLC Admission to the Official List 18 July 2007, Chippenham, UK - Vectura Group plc ("the Company") (LSE: VEC), thepulmonary product development Company focused on respiratory and neurologicaldiseases, is pleased to announce today that admission to the Official List ofthe UKLA (the "Official List") of 315,334,490 ordinary shares ("Ordinary Shares")has occurred ("Admission") and that trading in its Ordinary Shares will become effective from 8.00 a.m. today. Dr Chris Blackwell, Chief Executive of Vectura, commented: "Today's move to the Main Market is an important stage of the Company'sevolution, and is evidence of the strong progress that we have made since welisted on AIM in 2004. We look forward to welcoming new investors into Vectura,and we believe that the Main Market will enable us to further continue ourcommitment in growing and developing the Company." The Prospectus dated 17 July 2007, published in connection with the Admissionhas been submitted to the UK Listing Authority ("UKLA") and copies are availablefor inspection at the UKLA's document viewing facility, which is situated at: Financial Services Authority, 25 The North Colonnade, Canary Wharf, London E145HS. Copies of the Prospectus are also available from the Company's registered officeor from its website for a period of one month. - Ends - Enquiries: Vectura Group plc +44 (0)1249 667 600Dr Chris BlackwellAnne HylandJulia Wilson Piper Jaffray +44 (0)20 3142 8700David RasoulyWill Carnwath Financial Dynamics +44 (0)20 7831 3113David YatesJohn Gilbert About Vectura Vectura is a pulmonary drug development company focused principally on thedevelopment of a range of inhaled therapies for the treatment of respiratory andneurological diseases. The respiratory market is forecast to achieve sales of$32 billion by 2011. Vectura develops products to treat respiratory diseasessuch asthma, COPD and cystic fibrosis. Vectura also develops products whereoptimised delivery via the lungs into the blood stream can provide significantbenefits, such as a rapid onset of action, improved efficacy and improvedtolerability compared with current therapies. Vectura has eight marketed products and a portfolio of drugs in clinical andpre-clinical development, some of which have been licensed to majorpharmaceutical companies. The Company also seeks to develop certain programmesfurther through development to optimise value at a later licensing stage.Vectura also offers its formulation and inhalation technologies to otherpharmaceutical companies on a licensing basis where this complements Vectura'sbusinessstrategy. Vectura has development collaborations with a broad range of pharmaceuticalcompanies including Boehringer Ingelheim, Novartis, and Chiesi. The acquisitionof Innovata in January 2007 brought established alliances with a number ofadditional companies, such as Baxter, GSK, Merck KGaA, UCB and Otsuka as wellproviding revenue streams, complementary products and critical mass. For further information, please visit Vectura's website at www.vectura.com This press release contains "forward-looking statements," including statementsabout the discovery, development and commercialisation of products. Variousrisks may cause Vectura's actual results to differ materially from thoseexpressed or implied by the forward-looking statements, including adverseresults in clinical development programs; failure to obtain patent protectionfor discoveries; commercial limitations imposed by patents owned or controlledby third parties; dependence upon strategic alliance partners to develop andcommercialise products and services; difficulties or delays in obtainingregulatory approvals to market products and services resulting from developmentefforts; the requirement for substantial funding to conduct research anddevelopment and to expand commercialisation activities; and product initiativesby competitors. As a result of these factors, prospective investors arecautioned not to rely on any forward-looking statement. We disclaim anyintention or obligation to update or revise any forward-looking statements,whether as a result of new information, future events or otherwise. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
VEC.L